Artelo Biosciences, Inc. (ARTL) vs Bluejay Diagnostics, Inc. (BJDX)

A side-by-side comparison of Artelo Biosciences, Inc. and Bluejay Diagnostics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Artelo Biosciences, Inc. logo
ARTL
Artelo Biosciences, Inc.
$1M
$3.63HealthcareDelayed quote: Oct 6, 2026, 10:34 AM EDT
Bluejay Diagnostics, Inc. logo
BJDX
Bluejay Diagnostics, Inc.
$825702
$0.80HealthcareDelayed quote: Oct 6, 2026, 10:34 AM EDT

Total return — ARTL vs BJDX

growth of $100 · dividends reinvested · last 5y
ARTL -99.5% (-66.1%/yr)BJDX -100.0% (-91.5%/yr)ARTL compounded faster over this window
Log scale — wide-divergence pair
0000110100Start $10020222023202420252026$0$0
ARTL BJDX

ARTL vs BJDX: by the numbers

  • •ARTL is the larger company ($1M vs $825702 market cap).

Metrics side by side

Valuation

MetricARTLBJDX
P/B ratio0.280.09

Profitability

MetricARTLBJDX
Gross margin0.00%0.00%
Operating margin0.00%0.00%
Net margin0.00%0.00%
ROE-253.57%-77.23%
ROIC-219.36%-77.55%

Growth (annualized)

MetricARTLBJDX
Total return CAGR (5Y)-64.27%N/A

Go deeper

Full ARTL analysisFull BJDX analysisInteractive comparison tool

Dig into the metrics

Artelo Biosciences ROEBluejay Diagnostics ROEArtelo Biosciences operating marginBluejay Diagnostics operating marginArtelo Biosciences revenue growthBluejay Diagnostics revenue growthArtelo Biosciences free cash flowBluejay Diagnostics free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.